Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Other Non-Current Liabilities data on record, last reported at $30.0 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities changed N/A year-over-year to $30.0 million; the TTM value through Sep 2025 reached $30.0 million, changed N/A, while the annual FY2024 figure was $18.0 million, 41.94% down from the prior year.
  • Other Non-Current Liabilities reached $30.0 million in Q3 2025 per INDV's latest filing, up from $18.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $474.0 million in Q4 2021 and bottomed at $17.0 million in Q1 2025.
  • Average Other Non-Current Liabilities over 5 years is $145.1 million, with a median of $30.0 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: fell 9.7% in 2022, then crashed 92.76% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $474.0 million in 2021, then decreased by 9.7% to $428.0 million in 2022, then plummeted by 92.76% to $31.0 million in 2023, then plummeted by 41.94% to $18.0 million in 2024, then skyrocketed by 66.67% to $30.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $30.0 million in Q3 2025, $18.0 million in Q2 2025, and $17.0 million in Q1 2025.